March2Millions

🏖️ Trulieve Cannabis @Trulieve @Trulieve_IR (NYSE: $TRLV) is already drawing passive money from broad U.S. market and small-cap index products after its historic NYSE listing and S&P inclusion. 🚨 Tonight, after the close, investors find out whether the pure-play medical cannabis operator joins the Russell 2000 — potentially unlocking a new wave of mandatory buying in a sector still dominated by OTC trading and waiting on fuller federal normalization. Trulieve, the first major plant-touching U.S. cannabis multi-state operator to list on the NYSE (June 2026) after medical marijuana’s rescheduling to Schedule III, was added in September to the S&P Total Market Index, S&P Completion Index, and related health-care sub-indices. That opened the door to passive ownership by funds tracking those benchmarks. Index funds and ETFs already holding ~$60M TRLV Holdings data show a mix of thematic cannabis vehicles and passive broad-market/small-cap products: - AdvisorShares Pure US Cannabis ETF ($MSOS): The largest disclosed holder, with roughly 15% of TRLV’s shares outstanding and a ~23% weighting in the fund itself (MSOS AUM in the high hundreds of millions). This is active/thematic exposure rather than pure index tracking. - Vanguard Extended Market ETF ($VXF) and Vanguard Total Stock Market ETF (VTI): Direct beneficiaries of the S&P Completion and Total Market additions; together they account for a meaningful slice of the passive ownership. - Schwab U.S. Small-Cap ETF ($SCHA) and Schwab U.S. Broad Market ETF ($SCHB) - iShares Core S&P Total U.S. Stock Market ETF ($ITOT) - First Trust small-cap AlphaDEX funds ($FYC, $FYX) and a handful of smaller or multi-cap products. Collectively, tracked ETFs report ownership in the high teens percent of shares (hundreds of millions in value), with Vanguard products alone representing about 2%. These positions largely stem from the post-NYSE/S&P eligibility rather than Russell membership. Pure Russell 2000 trackers such as the iShares Russell 2000 ETF ($IWM, ~$77–78 billion AUM) and Vanguard’s Russell 2000 vehicle ($VTWO) do not yet hold TRLV at scale because it is not currently a constituent. How to find out today after the close FTSE Russell’s December 2026 reconstitution schedule is clear: Rank Day was October 30. Preliminary additions and deletions are published after the U.S. market close today, Friday, November 13. A query period follows (roughly November 16–27), with updates and a lockdown later in the month. Changes take effect after the close on December 11, with markets opening December 14 under the new membership. Check the FTSE Russell / LSEG site (russell-reconstitution resources and notices), major newswires, or company channels after 4 p.m. ET. Some quantitative shops and specialist commentators have flagged TRLV as having cleared the key screens (exchange listing, U.S. domicile after Delaware domestication, float, size, etc.), but the official preliminary list is the confirmation. Estimates from those analyses suggest that full inclusion could require index funds to buy on the order of 10–15 million shares around the reconstitution window—material relative to typical daily volume.[](>) Why this matters for cannabis Most of the cannabis sector still trades on the OTC with limited institutional participation. Federal Schedule I status historically created custody, banking, exchange-listing, and mandate barriers; even after Schedule III rescheduling enabled NYSE listing and S&P eligibility for pure medical operators like Trulieve (which spun out mixed-use assets), many institutions remain cautious pending further clarity on banking (e.g., SAFER-type legislation), adult-use policy, and tax treatment. Index inclusion changes the calculus: • Forced buying: Assets benchmarked to the Russell 2000 ($IWM alone is ~$77–78B; total tracking assets are substantially larger across ETFs and mutual funds) must own the stock in proportion to its index weight once it is added. That creates non-discretionary demand and improved liquidity. • Visibility and cost of capital: Higher trading volume, tighter spreads, and broader ownership can lower the cost of equity and make the stock more investable for managers who previously could not or would not touch OTC cannabis names. • Template effect: As the top holding in $MSOS and a scaled medical operator with strong Florida and other state positions, strong cash generation, and recent DEA registration progress, $TRLV ’s path (NYSE + S&P + potential Russell) is being watched as a blueprint for other larger MSOs once they clear similar eligibility hurdles. • Still early: Even with Schedule III, the sector has not yet seen full institutionalization. Index buying is a meaningful incremental step while the industry continues to wait for broader rescheduling effects, banking access, and clearer federal frameworks. It does not remove operational or regulatory risks, but it does expand the buyer base beyond retail and specialized cannabis funds. In short, today’s after-close preliminary list is the next concrete data point in cannabis’s gradual move from OTC niche to mainstream small-cap index eligibility. Confirmation of Russell 2000 addition would mark another milestone in that process; absence would simply mean the company remains outside that particular passive bucket for now while it continues to benefit from the S&P Total Market/Completion ownership already in place. 🇺🇸🌿🧺 $MSOS